P I Industries Q1 FY27 Results (NSE: PIIND)
Signal: Revenue declined
The read
The operating inflection is not yet established: consolidated revenue improved 8.8% QoQ to ₹17,023 million, but EBITDA margin fell 170bps YoY to 25.3% and PAT fell 37.7% to ₹2,442 million; the key thesis risk remains the pharma segment's ₹816 million loss, while ₹641 million of other income equalled 20% of PBT.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,702.3 Cr | -10.4% | +8.8% |
| EBIT | ₹327.8 Cr | -35.5% | |
| Net profit | ₹276.2 Cr | -37.7% | |
| EPS | ₹16.1 | -38.9% | |
| EBIT margin | 25.3% |
P&L walk
Consolidated revenue declined 10.4% YoY but rose 8.8% QoQ; EBITDA fell 28.7% and margin contracted to 25.3%, while PAT fell 37.7% despite ₹641 million of other income, reflecting continued pharma drag and weaker operating earnings.
Segments
Agro chemicals remained the group engine with ₹16,488 million of revenue and ₹3,835 million of segment profit, while pharma revenue fell 25.0% to ₹542 million and its loss widened to ₹816 million, dragging consolidated earnings materially below standalone performance.
Key positives
- Agro chemicals generated ₹3,835 million of segment profit on ₹16,488 million of revenue, with segment assets up 9.9% YoY to ₹124,549 million.
- Standalone revenue recovered 14.9% QoQ to ₹15,989 million and standalone PAT rose 72.7% QoQ to ₹3,415 million after the prior quarter's exceptional loss.
- Other expense was broadly stable YoY at ₹3,324 million despite revenue declining 10.4%, providing some cost containment.
Key concerns
- Consolidated EBITDA declined 28.7% YoY to ₹4,315 million and EBITDA margin contracted 170bps to 25.3%.
- Pharma segment revenue declined 25.0% YoY to ₹542 million and segment loss widened to ₹816 million from ₹760 million, creating a ₹1,257 million consolidated-versus-standalone PAT gap.
- Employee expense rose 12.3% YoY to ₹2,608 million as consolidated revenue fell 10.4%, lifting employee cost intensity to 15.3% from 12.2%.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.